← Back to Search

Diagnostic Test

Three imaging techniques: PET-MPI, CT-MPI, and CT-FFR for Coronary Artery Disease

N/A
Recruiting
Led By Carlo De Cecco, MD, PhD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 (day of scans)
Awards & highlights

Study Summary

This trial is comparing two different ways of measuring heart function: one using CT scans and one using PET scans. The goal is to see if CT scans are as accurate as PET scans.

Who is the study for?
This trial is for individuals who need a CT scan to check for coronary artery disease and are willing to follow the study's procedures. They must not be pregnant, nursing, or have taken certain diabetes medications recently. People with implanted heart devices, severe allergies to contrast material used in scans, kidney issues, low blood pressure, or specific heart rhythm problems cannot participate.Check my eligibility
What is being tested?
The MATCH Investigation aims to compare two types of heart imaging tests: CT scans that measure blood flow and blockages in the heart arteries (CT-MPI and CT-FFR) against PET scans known as PET-MPI which is considered the gold standard.See study design
What are the potential side effects?
Possible side effects include allergic reactions to contrast dye or stress agents used during imaging like Regadenoson. There might also be discomfort from lying still during scanning and exposure to radiation typical of medical imaging.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 (day of scans)
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 (day of scans) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Coronary Flow
Detection of Coronary Stenosis
Detection of Myocardial Perfusion Abnormalities
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Three imaging techniques: PET-MPI, CT-MPI, and CT-FFRExperimental Treatment4 Interventions
Participants referred for a clinical PET-MPI will also have CT-MPI and CT-FFR imaging performed for analysis of myocardial perfusion.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CT-FFR
2022
N/A
~520
Regadenoson
2012
Completed Phase 4
~5300

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,638 Previous Clinical Trials
2,560,512 Total Patients Enrolled
29 Trials studying Coronary Artery Disease
11,325 Patients Enrolled for Coronary Artery Disease
Siemens Medical SolutionsIndustry Sponsor
24 Previous Clinical Trials
3,708 Total Patients Enrolled
3 Trials studying Coronary Artery Disease
604 Patients Enrolled for Coronary Artery Disease
Carlo De Cecco, MD, PhDPrincipal InvestigatorEmory University

Media Library

CT-FFR (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT04316676 — N/A
Coronary Artery Disease Research Study Groups: Three imaging techniques: PET-MPI, CT-MPI, and CT-FFR
Coronary Artery Disease Clinical Trial 2023: CT-FFR Highlights & Side Effects. Trial Name: NCT04316676 — N/A
CT-FFR (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04316676 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~4 spots leftby Dec 2024